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ABSTRACT: The purpose of this study was to encapsulate neurotoxin-I (NT-I) within polylactic
acid (PLA) nanoparticles (NPs) and to evaluate their transport into the brain after intranasal
administration (i.n.) using a microdialysis sampling technique. NT-I-NPs (NT-I radiolabeled with
sodium [125I]iodide) were prepared and characterized. Then, NT-I-NPs were administered i.n. or i.v.
to rats and the radioactivities in the olfactory bulbs were monitored for up to 240 min. The
nanoparticles prepared were spherical with a homogenous size distribution. The mean particle size,
zeta potential and entrapment efficiency were 28.6 2.3 mV, 65 nm and 35.5 2.8%, respectively.
The brain transport results showed that the time to reach the peak level (Tmax) of NT-I-NPs (i.n.)
was 65 min, shorter than NT-I-NPs (i.v.) (95 min) or NT-I (i.v.) (145 min). The concentration at peak
level (Cmax) and the total area under the concentration–time curves from zero to 4 h (AUC0–4 h) of
each group followed the following order: NT-I-NPs (i.n.)>NT-I-NPs (i.v.)>NT-I (i.v.). The
corresponding absolute bioavailabilities (Fabs) of NT-I-NPs (i.n.) were about 160%, 196% with
NT-I-NPs (i.v.) and NT-I (i.v.) as reference preparations, respectively. The brain delivery of NT-I
could be enhanced with PLA nanoparticles either through i.n. or i.v. administration. Furthermore,
the enhancement was more significant for i.n. than for i.v. administration. Nanoparticles as carriers
would be a potential way to improve the brain transport for centrally active peptides. Copyright #
2008 John Wiley & Sons, Ltd.
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Introduction
The delivery of drugs to the central nervous
system (CNS) remains a challenge despite a
significant improvement in the mechanism gov-
erning the maintenance of brain homeostasis.
Specifically, the blood–brain barrier (BBB), fea-
turing tight continuous circumferential junctions
between the brain micro-vessel endothelial cells
(BMECs), hinders water-soluble molecules and
those with a molecular weight above 500 Da,
such as therapeutic peptides, proteins, genes and
antibiotics being delivered from the circulation
system to the brain [1,2]. The routine approaches
applied for the enhancement of drug concentra-
tions in the brain involve craniotomy-based drug
delivery, such as intraventricular drug diffusion,
local intracerebral implants, or disruption of the
BBB by infusion of hyperosmotic solutions or
vasoactive agents prior to systemic administra-
tion of the drugs. Being highly invasive, these
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approaches are most appropriate for short-term
treatments, where a single or infrequent exposure
to a drug is required [3], but not an ideal method
for long-term treatments.
Due to the formidable obstacle imposed by the
BBB, there has been increased interest in devel-
oping strategies to overcome the BBB barrier. It
has been a widely held view that intranasal (i.n.)
administration provides a means of circumvent-
ing the BBB and thus may allow increased CNS
penetration of compounds that otherwise display
limited CNS exposure [4]. In general, there are
three pathways that a drug administered into the
nasal cavity may travel. These routes include
entry into the systemic circulation direct from the
nasal mucosa, entry into the olfactory bulb via
axonal transport along neurons, and direct entry
into the brain via the olfactory epithelium. A
drug that enters into the systemic circulation
should be absorbed through the nasal mucosa.
Administration via this route avoids the hepatic/
gastrointestinal first-pass effects and therefore
may provide more extensive systemic exposure
for substrates that have poor oral bioavailability
(such as proteins or peptides etc.) [5]. Large
molecules such as nerve growth factor (NGF)
were reported to achieve significantly higher
brain concentrations by i.n. administration than
that by systemic administration at the same dose.
The effectiveness of this route for enhancing the
brain delivery of large molecules, including
vasopressin, cholecystokinin, insulin and insu-
lin-like growth factor-1, was demonstrated in
both humans and animals. These results suggest
that the nasal pathway functions for the direct
delivery of drugs into the brain [6].
Another possibility of delivering drugs to the
brain is by the use of nanoparticles. Nanoparti-
cles for pharmaceutical and chemical use are
defined as polymeric particles made of natural or
artificial polymers ranging in size between about
10 and 1000 nm [7]. Drugs may be bound in the
form of a solid solution or dispersion, or
adsorbed to the surface or chemically attached.
Loaded by nanoparticles, the drugs will be
released at an appropriate rate and dose at
specific sites in the body during a certain time
to achieve accurate delivery, which will enhance
the therapeutic efficacy and reduce toxicity and
side effects [8]. It has been reported that
nanoparticles overcoated with polysorbates
(especially polysorbate 80) were capable of
transporting the loaded drugs across the BBB
after administration, which functioned as a tool
to deliver drugs to the brain. Up to now, most
studies have focused on nanoparticles of poly
(butylcyanoacrylate) (PBCA), a polymer that is
not authorized for use in humans [9–12]. How-
ever, PBCA will be degraded rapidly by esterases
present in biological fluids and its toxic products
will stimulate or damage the CNS [13]. At
present, brain targeting is mainly characterized
by the physiological or pharmacological reac-
tions of tested animals that were administered
model drugs mediated by nanoparticles [3,10,14].
No study on concentration–time profiles of brain
transport of drug-loaded nanoparticles has yet
been reported.
The objective of this work was to evaluate the
brain transport of large molecular weight drug-
loaded nanoparticles after i.n. administration. A
new microdialysis sampling technique was used
in the elementary work. Neurotoxin-I (NT-I), an
analgesic peptide with limited permeability
across the BBB which was separated from the
venom of Naja naja atra [15,16], was selected as a
model drug for this study. PLA, a typical
biodegradable polyester currently employed in
the clinic approved by Food and Drug Agency of
USA, was employed instead of PBCA to avoid
the toxic effects induced by the matrix material.
Materials and Methods
Chemicals
NT-I (m.w. of 6900 Da; purity of 99.3%) was
provided by Kunming Institute of Zoology, the
Chinese Academy of Sciences (Jiaochang East
Road No. 32, Kunming City in Yunnan Province).
[125I]NT-I (3.8 mCi/0.90 mg; 800 ml) was supplied
by Fudan University (Medical Road No. 138,
Shanghai City, China). PLA (m.w. of 11 KDa) and
sodium cholate were purchased from Sigma-
Aldrich Corporation (St Louis, MO, USA). Ethyl
acetate (analytical grade) and polysorbate-80
were products from Huadong Medicine Group
Co. (Qingtai Road No. 350, Hangzhou City,
China). Other reagents were analytical grade.
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Animals
The protocol for this study was approved by the
Care and Use of Animals of the Zhejiang
University (Yugu Road No. 20, Hangzhou City,
China). Twenty male adult Sprague-Dawley rats,
13 weeks old and weighing 350 g were purchased
from the Laboratory Animal Center of Zhejiang
Academy of Medical Sciences (Zhejiang, China).
They were maintained in a climate controlled
room acclimatized for at least 5 days kept at a
temperature of 22 18C with 12 h light–dark
cycles and a relative humidity of 60 10%. Water
and standard laboratory food (Zhejiang Acad-
emy of Medical Sciences, Tianmushang Road No.
182, Hangzhou City, China) were available
ad libitum.
Preparation of nanoparticles
The procedures used for preparing the nanopar-
ticles were similar to the reported double
emulsification solvent evaporation method
[17,18]. Briefly, a 50 ml aliquot of the above
[125I]NT-I solution containing 56 mg of toxin was
emulsified in 1 ml of PLA in ethyl acetate (50 mg/
ml) by sonication (JY92-IID, Ningbo Scientz
Biotechnology Co. Qianfeng Road No. 9, Ningbo
City in Zhejiang Province, China) on an ice-bath
for 30 s (40 w). Then, 2 ml of aqueous sodium
cholate solution (1%, w/v) was added and the
resulting (w/o)/w emulsion was sonicated for
20 s (40 w). The double emulsion was diluted in
100 ml aqueous sodium cholate solution (0.3%,
w/v) and the solvent was rapidly eliminated by
evaporation under vacuum. Finally, the nanopar-
ticles were isolated by centrifugation [22000 g,
30 min (J2-HS, Beckman Coulter, 4300 N. Harbor
Blvd. Fullerton, CA 92834-3100)], washed three
times with water and lyophilized. Polysorbate 80
was added at a ratio of 1:1 (w/w) to reconstitute
nanoparticles and incubated for 30 min.
Physicochemical characterization of
nanoparticles
The morphological examination of nanoparticles
was performed using a transmission electron
microscope (TEM, JEM-1200EX, Jeol, Tokyo,
Japan) following negative staining with sodium
phosphotungstate solution (0.2%, w/v). The
particle size distribution and zeta potential of
nanoparticles were determined using a Zetasizer
3000HSA (Malvern, England).
Determination of encapsulation efficiency
Nanoparticles containing [125I]NT-I were pre-
pared using the procedure indicated above,
centrifuged and the supernatants were assessed
in a SN-682 gamma-counter (Rihuan Instrument
Factory of Shanghai Atomic Nuclide Institute,
Shanghai City, China). The amount of NT-I
encapsulated into the nanoparticles was calcu-
lated by the difference between the total amount
used to prepare the nanoparticles and the
amount of NT-I present in the aqueous phase.
Surgical procedures
Rats were anesthetized with intraperitoneal
ketamine (90 mg/kg)+xylazine (10 mg/kg) and
mounted on a stereotaxic frame (Bioanalytical
Systems, West Lafayette, IN, USA), as reported
[19]. Briefly, a 0.5 mm hole was drilled in the rat
skull separately (right olfactory bulb: 1.0 mm
lateral to the midsagittal suture and 6.0 mm
anterior to bregma). One chronic brain micro-
dialysis guide cannula (MD-2251, BAS, West
Lafayette) with styles in place was inserted into
the brain aimed at the right olfactory bulb
identical to a depth of 4.6 mm ventrally from
the dura according to the Rat Brain Atlas of
Paxinos and Watson [20]. The guide cannula was
fastened to the cranium with skull screws and
dental acrylic cement. After surgery, the animals
were allowed to recover for 6 days in single cages
under standard conditions, with free access to
food and water until 24 h before administration,
at which time only food was withdrawn.
Recovery determination
The retrodialysis recoveries of the drug [125I]NT-I
in vitro and in vivo were determined as described
below prior to probe implantation. The retro-
dialysis recoveries in vivo by the loss of [125I]NT-I
were used for further recalculations of the true
extracellular drug concentrations at the sampling
site of the olfactory bulb.
Both recoveries in vitro obtained by the
difference between gain and loss (retrodialysis)
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before the rat experiments of three probes of the
same type for use in brain (MD-2200, BAS, West
Lafayette) with characteristics of 0.5 mm (o.d.),
2 mm (membrane length), and nominal 38 kDa
[mw cut-off of four concentration levels (1, 5, 10
and 15 ng/ml)], were investigated at a flow rate
of 2.0 ml/min. Thus, the recoveries in vitro (gain
and loss) for [125I]NT-I were 25.4% and 28.7%,
respectively; they were not significantly different
(p>0.05). No difference among the three indivi-
dual probes was shown (p>0.05). The recoveries
in vitro (gain and loss) were used only to evaluate
the functional properties of each probe.
The recovery in vivo by the loss of [125I]NT-I for
each probe at the olfactory bulb was calculated





in which CNT-I and the [
125I]NT-I concentration,
given for dialysate, perfusate and BIF (brain
interstitial fluid), respectively. During the retro-
dialysis period, the concentration of [125I]NT-I in
BIF was assumed to be zero because of its relative
high diffusion coefficient in brain tissues. Three
samples (20 ml per sample) from each period were
collected and analysed over 10 min intervals (first
two and last samples discarded). The recovery
in vivo (n=12) of 125I-NT-I (loss) was also
conducted on the same type probes as those in
in vitro recovery experiments with four concen-
tration levels (1, 5, 10 and 15 ng/ml). All
statistical analyses (ANOVA) were performed
using Origin 6.0 (Microcal Software, Inc., North-
ampton, MA, USA).
Brain transport of nanoparticles
At the beginning of the experiment, potassium
iodide (40 mg/kg) was orally administered in
case of deposition in the thyroid gland. Then the
rats were randomly divided into four groups
(n=5, each group); group 1 and 2 rats were
administered intranasally with NT-I-NPs (45 mg
lyophilized nanoparticles was dissolved in
0.15 ml PBS with addition of 1:1 (w/w) poly-
sorbate 80, 17 mg/kg) and free NT-I solution,
respectively. Each animal was dosed intranasally
by instilling 80 ml in each nostril (15 ml three times
in 3 min time-intervals) of the preparations. A
supine-70 position was employed in rats con-
trolled using a home-made patent device when
the nasal formulations were dosed. Nasal pre-
parations were administered using a soft PE-10
tubing (Becton Dickinson and Co., Sparks, Mary-
land, USA) fitted to a 50 ml Hamilton microsyr-
inge, inserting 15 mm into the cavity in the right
nostril [21]. Groups 3 and 4 were treated
intravenously with the same formulations as
groups 1 and 2 (dose, 115 mg/kg). All micro-
dialysis experiments were performed in the
awake state (freely moving) kept in an awake
animal caging system (Stand-Alone Raturn and
Rodent Bowl kit, BAS, West Lafayette), with no
anaesthesia used throughout the experiment.
On the day of the experiment, the brain
microdialysis probe (MD-2200) was inserted into
the guide cannula, 30 min before sampling was
begun. The inlet of the probe was attached to a
BAS syringe driver (MD-1001, BAS, West Lafay-
ette, USA) connected as a controller (240V/50 Hz
MD-1000 K, BAS, West Lafayette), filled with a
modified Ringer’s solution as perfusion fluid
(145 mm NaCl, 3.7 mm KCl, 1.0 mm MgCl2, 1.2 mm
CaCl2, 10 mm NaHCO3, 0.1 mm ascorbic acid, pH
7.4). The brain microdialysis probe was simulta-
neously perfused at a flow rate of 2 ml/min for
30 min (delay time) and all microdialysates
collected were discarded in order to eliminate
the void volume in tubing and to stabilize solute
levels around the dialysis membrane before
starting to collect samples. After this equilibrium
period, brain microdialysate samples were col-
lected using a refrigerated fraction collector (MD-
1201, BAS, West Lafayette) into 300 ml vials at a
10 min sampling regime automatically continued
for 240 min (sample volume of 20 ml per vial).
After each experiment, the animals were
anesthetized with excessive amount of chloral
hydrate and transcardially perfused with 4%
paraformaldehyde in 0.1m Srenson buffer as
described previously [22]. The brains were
dissected out, immediately frozen and stored at
208C. Coronal 40 mm thick slices were later cut
with a cryo-microtome and the unstained sec-
tions were observed under magnification to
localize the probe tract. Only animals with the
probe located in the olfactory bulb and cerebellar
nuclei were included in the present study.
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Data analysis
Data are presented as mean SD. A two-tailed
Student’s t-test was used to evaluate the statis-
tical significance of differences between experi-
mental groups. In all cases, p50.01 was used as a
criterion for statistical significance.
The time to reach peak level (Tmax) and peak
concentrations (Cmax) were directly obtained from
the observed data of the concentration–time curves.
The total area under the concentration–time curve
from time zero to 5 h (AUC0–4 h) was calculated
using the linear trapezoidal rule method.
Results
Physicochemical characteristics of nanoparticles
Nanoparticles were initially characterized for
morphology, particle size distribution, zeta po-
tential and encapsulation efficiency. As can be
seen in Figures 1 and 2, nanoparticles were
spherical with a homogenous size distribution
and had a sub-micron particle size (65 nm). The
zeta potential of the nanoparticles was
28.6 2.3 mV. NT-I could be encapsulated
efficiently in nanoparticles (35.5 2.8% encapsu-
lation efficiency). Nanoparticles were stable by
lyophilization and in various buffers.
Recovery determination of microdialysis probes
Average recovery by loss (retrodialysis) in vivo
(n=12) of three brain probes (MD-2200) with four
concentrations of [125I]NT-I used in the right
olfactory bulb of the rat was 14.1% ( 1.2%)
(p>0.05). This was used to correct the actual
concentration of NT in dialysates sampled from
the right olfactory bulb in rats.
Brain transport of nanoparticles
The present results showed that the brain
delivery of NT-I could be enhanced with PLA
nanoparticles either via i.n. or i.v. administration.
The enhancement was more significant for i.n.
administration than for i.v. administration. The
concentration–time curves from different groups
are shown in Figure 3.
The transport parameters, Tmax, Cmax and
AUC0–4 h from different groups are shown in
Table 1. These results suggest that PLA nano-
particles play an important role in the transport
of NT-I to the brain. These results are in
good agreement with previously reported results
[9–12].
Discussion
Centrally active proteins and peptides with poor
bioavailability and severe limitation of BBB
penetration have been increasingly developed,
which makes the administration mode more
challenging. Recent developments have gradu-
ally revealed that i.n. administration is a promis-
ing alternative for brain delivery for large
molecular weight drugs [23]. A drug adminis-
tered by the nasal route may primarily enter the
blood of the general circulation and then pene-Figure 1. Transmission electron micrography of NT-I-NPs
Figure 2. Particle size distribution of NT-I-NPs
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trate across BBB into the CNS. However, this
mode of administration may also allow circum-
vention of the BBB, thereby delivering drugs
directly into the brain. With the advance of
nanotechnology, polymer nanoparticles can be
employed as carriers to transport the entrapped
or adsorbed drugs across the BBB. Since Kreuter
et al. first reported that polysorbate 80-coated
PBCA nanoparticles could deliver the peptide
dalargin into CNS to exert its analgesic effect in
1995 [24], several drugs have been successfully
delivered into the brain by this colloidal carrier.
Our present findings suggest that nanoparticles
could exert enhanced delivery of NT-I into the
brain. The enhancement was more significant
after i.n. administration.
The present results on brain transport showed
that the Tmax (approximately 65 min) of NT-I-NPs
(i.n.) was shorter than that of NT-I-NPs (i.v.)
(95 min) and NT-I (i.v.) (145 min). It seemed that
the brain delivery speed was quicker for NT-I-
NPs (i.n.) than that for NT-I-NPs (i.v.) and NT-I
(i.v.). The difference in either Cmax or AUC0–4 h
among these three groups were significant
(p50.01). The corresponding absolute bioavail-
ability (Fabs) of NT-I-NPs (i.n.) were about 160%,
196% with NT-I-NPs (i.v.) and NT-I (i.v.) as
reference preparations respectively. It implied
that the brain delivery of NT-I could be enhanced
with NPs as carriers and being administered
intranasally, this being consistent with Zhang’s
conclusion. Zhang et al. demonstrated that
MPEG-PLA nanoparticles showed a potential
for improving the efficacy of the direct nose–
brain transport for drugs [25]. These results
indicate that although the majority of drugs
would be absorbed into the systemic circulation
through the nasal mucosa, and a small amount of
drug would be delivered direct from the nasal
cavity. Several studies have shown a direct route
of transport from the olfactory region to the CNS
in animal models, without prior absorption into
the circulating blood [26–28]. For instance, in our
previous study, with borneol–menthol eutectic
mixture as an absorption enhancer, NT-I could be
transported direct from the nasal cavity to the
brain [29]. Although i.n. administration has been
used for brain delivery of some drugs, a
comprehensive understanding of the mechan-
isms governing this pathway is necessary in
Figure 3. Mean concentration–time curves in the olfactory bulbs from rats of NP-I-NPs (m i.n., ^ i.v.) and NT-I (& i.v.). Data are
mean SD (n=5)
Table 1. Brain transport parameters of NT-I-NPs or NT-I through i.n. or i.v. administration. Data are mean SD (n=5)
Parameter NT-I-NPs (i.n.) NT-I-NPs (i.v.) NT-I (i.v.)
Tmax (min) 65 95 145
Cmax (ng/ml) 15.411.11 10.22 1.03 8.30 0.67
AUC0–4 h (ng min/ml) 2000 52.11
ab 1250 31.41 1020 30.83
ap50.01 compared with NT-I-NPs (i.v.); bp50.01 compared with NT-I (i.v.).
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order to investigate the potential use of nasal
administration as a practical means of delivery of
agents to the brain. There are three nose–brain
pathways proposed as modes for a drug to reach
the CNS from the nasal cavity: transcellular
pathway, paracellular pathway and intracellular
axonal transport [30]. However, whether or not
the NT-I-NPs could be delivered to the brain
through the direct nose–brain pathway needs to
be studied further.
From the current results, it was found that both
the Cmax and AUC0–4 h of the three groups was as
follows: NT-I-NPs (i.n.)>NT-I-NPs (i.v.)>NT-I
(i.v.). These results suggest that nanoparticles
could significantly improve the drug transport to
the brain either through i.n. or i.v. administration.
This conclusion was demonstrated by many
other investigators. For example, Gao et al. found
that nanoparticles overcoated by polysorbate 80
could notably enhance the drug level into both
the brain tissues and cerebrospinal fluids after i.v.
administration compared with uncoated ones
and simple solution [31]. The first drug that
was transported across the BBB with nanoparti-
cles as carriers was dalargin. After adsorption to
the nanoparticles and i.v. injection, dalargin led
to a dose- and time-dependent antinociceptive
effect using the tail-flick test as well as in the hot
plate test [10,14,24,32]. Other drugs that have
been transported across the BBB using the
polysorbate 80-coated PBCA nanoparticles in-
cluding kytorphin (dipeptide), loperamide, tubo-
curarine, MRZ 2/576 and MRZ 2/596 (NMDA-
receptor antagonists), doxorubicin, methotrexate
[7,24,31], etc.
A number of possibilities exist that could
explain the mechanisms of the delivery of the
above mentioned substances across the BBB
[7,12,33]: (1) An increased retention of the
nanoparticles in the brain blood capillaries
combined with an adsorption to the capillary
walls. This could create a higher concentration
gradient that would enhance the transport across
the endothelial cell layer and delivery into the
brain. (2) A general surfactant effect character-
ized by a solubilization of the endothelial cell
membrane lipids that would lead to membrane
fluidization and an enhanced drug permeability
through the blood–brain barrier. (3) The nano-
particles could lead to an opening of the tight
junctions between the endothelial cells. The drug
could then permeate through the tight junctions
as a free form or together with the nanoparticles
in bound form. (4) The nanoparticles may be
endocytosed by the endothelial cells followed by
the release of the drugs within these cells and
delivery to the brain. (5) The nanoparticles as
bound drugs could be transcytosed through the
endothelial cell layer. (6) The polysorbate 80 used
as the coating agent could inhibit the efflux
system, especially P-glycoprotein (Pgp). All these
mechanisms also could work in combination. In
the present work, the mechanism of NT-I trans-
port into the brain with NPs as carriers after i.n.
administration remains to be further studied.
Microdialysis, originally developed to monitor
neurotransmitter concentrations in the brain, has
been proven by those who have used it, to be a
valuable method for studying drug delivery to
the CNS. The method saves animals, since many
data can be obtained within one experiment and
since it is possible to perform crossover experi-
ments in animals. The technique also provides
data on temporal aspects of drug delivery to the
CNS. With microdialysis it is possible to calculate
the ratios of drug concentrations in the brain ECF
to those in the blood, quantitating the influence
of active transport mechanisms at the BBB, in
order to estimate influx and efflux clearances that
are independent of binding in blood or brain
tissue, and to estimate the amount of binding that
takes place in blood and brain tissue.
Another advantage of microdialysis is that it
makes it possible to study hydrophilic drugs,
which is difficult with other in vivo methods. It is
also possible to estimate drug distribution within
brain tissue, i.e. whether the drug is distributed
mainly into brain ECF or whether it is also
transported intracellularly or bound to extracel-
lular components [34]. The results showed that
microdialysis is quite suitable for the brain
delivery research of drugs [34].
In conclusion, the brain delivery of NT-I could
be enhanced with PLA nanoparticles either
through i.n. or i.v. administration. The enhance-
ment is more significant for i.n. than for i.v.
administration. With nanoparticles as carriers,
i.n. administration would be a potential way to
deliver centrally active peptides to improve
their brain transport. Microdialysis is quite a
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good technique for the study of drug delivery to
the brain.
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